Immune checkpoints are regulators of immune activation by regulating the antigen recognition of T cell receptor (TCR) in the process of immune response. They play a key role in maintaining immune homeostasis and preventing autoimmunity. In cancer, immune checkpoint mechanisms are often activated to suppress the nascent anti-tumor immune response. This has led to the development of several checkpoint inhibitor antibody drugs that are currently being tested in clinical trials or have been approved for a number of cancers.

Part Target Products

The ED50 as determined by its ability to bind Mouse B7-1 in functional ELISA is less than 0.4 μg/ml. (Code: CSB-AP005121GU)

The ED50 as determined by its ability to bind Mouse B7-1 in functional ELISA is less than 20 μg/ml. (Code: CSB-AP005301MO)

The ED50 as determined by its ability to bind Human SIRPA in functional ELISA is less than 20 μg/ml. (Code: CSB-AP005201HU)

The ED50 as determined by its ability to bind Human CD47 in functional ELISA is less than 0.5 μg/ml. (Code: CSB-AP005271HU)